| Name | Kindred At Home |
|---|---|
| Location | 216 Mystic Blvd Suite H, Houma, Louisiana |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 197215 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 70039, 70063, 70301, 70340, 70342, 70343, 70344, 70345, 70353, 70354, 70356, 70359, 70360, 70363, 70364, 70372, 70373, 70374, 70377, 70380, 70381, 70390, 70392, 70394, 70395, 70397, 70538, 70767 |
| NPI Number | 1083606313 |
| Organization Name | SYNERGY HOME CARE-SOUTHEASTERN REGION INC |
| Doing Business As | CENTERWELL HOME HEALTH |
| Address | 5779 Highway 311 Ste 1, Houma, LA 70360 |
| Phone Number | 985-223-4321 |
News Archive
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.
Low C-reactive protein levels may identify obese people who are unlikely to develop cardiovascular complications over subsequent years, show data from the EPIC study.
Researchers at the University of Oslo have made discoveries that can have great consequences for the treatment of blindness caused by so-called limbal stem cell deficiency.
› Verified 5 days ago
| Quality Rating: |
News Archive
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.
Low C-reactive protein levels may identify obese people who are unlikely to develop cardiovascular complications over subsequent years, show data from the EPIC study.
Researchers at the University of Oslo have made discoveries that can have great consequences for the treatment of blindness caused by so-called limbal stem cell deficiency.
› Verified 5 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 99.8 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.6 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 99.8 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 81.4 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 80.3 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 100 | 96.4 |
News Archive
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.
Low C-reactive protein levels may identify obese people who are unlikely to develop cardiovascular complications over subsequent years, show data from the EPIC study.
Researchers at the University of Oslo have made discoveries that can have great consequences for the treatment of blindness caused by so-called limbal stem cell deficiency.
› Verified 5 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 84.3 | 79.6 |
| How often patients got better at getting in and out of bed | 85.2 | 81.1 |
| How often patients got better at bathing | 86.9 | 82.3 |
| How often patients’ breathing improved | 83.8 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 92.2 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 80.3 | 75 |
| How often home health patients had to be admitted to the hospital | 14.2 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 14.9 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 97.4 | 94 |
News Archive
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.
Low C-reactive protein levels may identify obese people who are unlikely to develop cardiovascular complications over subsequent years, show data from the EPIC study.
Researchers at the University of Oslo have made discoveries that can have great consequences for the treatment of blindness caused by so-called limbal stem cell deficiency.
› Verified 5 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.
Low C-reactive protein levels may identify obese people who are unlikely to develop cardiovascular complications over subsequent years, show data from the EPIC study.
Researchers at the University of Oslo have made discoveries that can have great consequences for the treatment of blindness caused by so-called limbal stem cell deficiency.
› Verified 5 days ago
The patient survey data of Kindred At Home is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 94 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 93 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 94 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 91 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 83 | 78 |
News Archive
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.
Low C-reactive protein levels may identify obese people who are unlikely to develop cardiovascular complications over subsequent years, show data from the EPIC study.
Researchers at the University of Oslo have made discoveries that can have great consequences for the treatment of blindness caused by so-called limbal stem cell deficiency.
› Verified 5 days ago
Amedisys Home Health Location: 1403 St Charles Street , Suite 101, Houma, Louisiana 70360 Ratings: Phone: (985) 872-1955 | |
Kindred At Home Location: 216 Mystic Blvd Suite H, Houma, Louisiana 70360 Ratings: Phone: (985) 223-4321 | |
The Medical Team Inc Location: 4722 Highway 311, Houma, Louisiana 70360 Ratings: Phone: (985) 872-6666 | |
Bayou Home Care, Llc Location: 232 Civic Center Blvd, Houma, Louisiana 70360 Ratings: Phone: (985) 580-2273 | |
Terrebonne Homecare, Inc. Location: 760 W Tunnel Blvd, Houma, Louisiana 70360 Ratings: Phone: (985) 873-7000 |